Lecanemab And Medicare: Could Better FDA/CMS Communication Improve Coverage Chances?

After Impact On Cognition Finally Demonstrated In Phase III Trial, will FDA, CMS and sponsors have a meeting of the minds? • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet